Abstract
There is ongoing debate on the safety of renin-angiotensin system (RAS) inhibitors in COVID-19. Recently published studies highlight a potential relationship between cardiovascular disease (CVD) and COVID-19. This article aims to summarize the evidence on the use of RAS inhibitors in CVD patients with COVID-19, focusing on safety issues of the RAS inhibitors and their relationship with COVID-19.
| Original language | English |
|---|---|
| Pages (from-to) | 217-221 |
| Number of pages | 5 |
| Journal | American Journal of Cardiovascular Drugs |
| Volume | 20 |
| Issue number | 3 |
| Early online date | 13 Apr 2020 |
| DOIs | |
| Publication status | Published - 1 Jun 2020 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19'. Together they form a unique fingerprint.-
Glucocorticoid versus immunoglobulin in the treatment of COVID-19-associated fulminant myocarditis
Kow, C. S. & Hasan, S. S., 1 Oct 2020, In: Infection. 48, 5, p. 805-806 2 p.Research output: Contribution to journal › Letter › peer-review
Open Access12 Link opens in a new tab Citations (Scopus) -
Is it worth the wait? Should Chloroquine or Hydroxychloroquine be allowed for immediate use in CoViD-19?
Hasan, S. S., Kow, C. S. & Merchant, H., 31 Mar 2020, In: British Journal of Pharmacy. 5, 1, 5 p., 745.Research output: Contribution to journal › Review article › peer-review
Open Access
Press/Media
-
Study says inhalers OK to use amid COVID-19 concerns
Merchant, H., Hasan, S. S., Capstick, T., Razi Zaidi, S. T. & Kow, C. S.
7/07/20 → 13/07/20
13 items of Media coverage
Press/Media: Research
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver